This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Reply to Is There a Real Difference Between the First Onset of Efficancy for Atypicla Antipsychotic Monotherapies in Acute Bipolar Mania?”

Paul E. Keck, Jr., MD

Published: October 14, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Dr. Treuer and Mr. Basson make an important point ofclarification regarding the onset of efficacy for atypical antipsychoticsin patients with acute mania. Although the data fromplacebo-controlled trials indicate that there were significantmean reductions in measures of manic symptoms from placeboat day 2 in patients receiving ziprasidone, at day 3 in patientsreceiving risperidone (in 1 trial), and at day 4 in patients receivingaripiprazole, these data should not be construed to implydifferences in onset of efficacy. They do indeed represent thetimepoints at which improvement was first assessed followingbaseline evaluations prior to randomization in these trials.’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: